*January 2021*

The combination of osimertinib (Tagrisso) plus bevacizumab (Avastin) failed to result in a statistically significant improvement in progression-free survival (PFS) versus osimertinib alone in patients with advanced lung adenocarcinoma that harbored an EGFR T790M mutation, according to findings from a phase 2 trial published in JAMA Oncology.

Results showed that the doublet elicited a higher overall response rate (ORR) than the monotherapy, at 71.8% versus 55.0%, respectively; however, this benefit with osimertinib/bevacizumab failed to translate to a significant PFS benefit over osimertinib alone, at 13.5 months versus 9.4 months, respectively (adjusted HR, 1.44; 80% CI, 1.00-2.08 and 95% CI, 0.83-2.52, respectively; P = .20).

“To our knowledge, this is the first randomized clinical trial to explore the efficacy of adding [an] anti-VEGF inhibitor to osimertinib,” Hiroaki Akamatsu, MD, PhD, Internal Medicine III, of the Wakayama Medical University, and colleagues, wrote in the paper. “Although ORR was slightly better in the combination arm, we could not show advantages in PFS and overall survival [OS].” Read more.